Kim Yundeok, Kim Soo Jeong, Hwang Dohyu, Jang Jieun, Hyun Shin Young, Kim Yu Ri, Kim Jin Seok, Min Yoo Hong, Cheong June Won
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Yonsei Med J. 2014 Nov;55(6):1568-75. doi: 10.3349/ymj.2014.55.6.1568.
The modified Glasgow Prognostic Score (mGPS) consisting of serum C-reactive protein and albumin levels, shows significant prognostic value in several types of tumors. We evaluated the prognostic significance of mGPS in 285 patients with diffuse large B cell lymphoma (DLBCL), retrospectively.
According to mGPS classification, 204 patients (71.5%) had an mGPS of 0, 57 (20%) had an mGPS of 1, and 24 (8.5%) had an mGPS of 2.
Our study found that high mGPS were associated with poor prognostic factors including older age, extranodal involvement, advanced disease stage, unfavorable International Prognostic Index scores, and the presence of B symptoms. The complete response (CR) rate after 3 cycles of R-CHOP chemotherapy was higher in patients with mGPS of 0 (53.8%) compared to those with mGPS of 1 (33.3%) or 2 (25.0%) (p=0.001). Patients with mGPS of 0 had significantly better overall survival (OS) than those with mGPS=1 and those with mGPS=2 (p=0.036). Multivariate analyses revealed that the GPS score was a prognostic factor for the CR rate of 3 cycle R-CHOP therapy (p=0.044) as well as OS (p=0.037).
mGPS can be considered a potential prognostic factor that may predict early responses to R-CHOP therapy in DLBCL patients.
由血清C反应蛋白和白蛋白水平组成的改良格拉斯哥预后评分（mGPS）在几种类型的肿瘤中显示出显著的预后价值。我们回顾性评估了mGPS在285例弥漫性大B细胞淋巴瘤（DLBCL）患者中的预后意义。
根据mGPS分类，204例患者（71.5%）的mGPS为0，57例（20%）的mGPS为1，24例（8.5%）的mGPS为2。
我们的研究发现，高mGPS与不良预后因素相关，包括年龄较大、结外受累、疾病晚期、国际预后指数评分不佳以及B症状的存在。R-CHOP化疗3个周期后的完全缓解（CR）率在mGPS为0的患者中（53.8%）高于mGPS为1的患者（33.3%）或mGPS为2的患者（25.0%）（p=0.001）。mGPS为0的患者的总生存期（OS）明显优于mGPS为1和mGPS为2的患者（p=0.036）。多变量分析显示，GPS评分是3周期R-CHOP治疗CR率（p=0.044）以及OS（p=0.037）的预后因素。
mGPS可被视为一种潜在的预后因素，可能预测DLBCL患者对R-CHOP治疗的早期反应。
